Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
DiMango, Emily, M.D.
With
Genentech, Inc.
Novartis
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-30
Minority Patients
Moderate or Severe allergic asthma (as defined by the National Asthma Education and Prevention Guidelines(7)\]. Allergic asthma will be defined as elevated IgE level (\> 100 IU/ml) and skin test sensitivity to at least one common aeroallergen
asthma control score greater than 1.5 (5) at randomization visit with use of equivalent of at least 1000 mcg fluticasone daily or systemic steroid use
FEV1 50-90% predicted at screening and randomization visit
You may not be if
Active smoking within one year and/or greater than 10-pack year history of smoking
Women of childbearing age must be using effective contraception
Malignancy diagnosed within the past 5 years
Underlying lung disease other than asthma
Inability to comply with study protocol
Clareo Health | Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
